Lovastatin modified release - Synthetic Biologics

Drug Profile

Lovastatin modified release - Synthetic Biologics

Alternative Names: SYN-010

Latest Information Update: 04 Aug 2016

Price : $50

At a glance

  • Originator Cedars-Sinai Health System
  • Developer Synthetic Biologics
  • Class Anti-inflammatories; Antihyperlipidaemics; Irritable bowel syndrome therapies; Naphthalenes
  • Mechanism of Action HMG-CoA reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Irritable bowel syndrome

Most Recent Events

  • 02 Aug 2016 Synthetic Biologics completes an end of phase II meeting with the US FDA
  • 15 Mar 2016 Biomarkers information updated
  • 10 Mar 2016 Synthetic Biologics plans to hold an end of phase II meeting with the US FDA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top